

# ASSOCIATION OF BREAST SURGERY CONFERENCE

13<sup>th</sup> & 14<sup>th</sup> May 2019 • SEC Glasgow

**ABS**  
ASSOCIATION OF  
BREAST SURGERY



# CONFERENCE PROGRAMME

[www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)



# We believe in **safety**

Visit us on stand 26

[www.gcaesthetics.com](http://www.gcaesthetics.com)

[f/gcaestheticsglobal](#) [t/G\\_C\\_Aesthetics](#) [in/company/gc-aesthetics](#)



# IT'S TIME to move forward

Discover a better way to test for breast cancer recurrence with Prosigna. Now you can quickly and reliably identify your patients' 10-year risk of distant recurrence.

- Risk assessment based on PAM50 intrinsic subtypes
- Prosigna selects a subset of patients with an estimated 10-year probability of distant recurrence of  $\leq 5\%$  regardless of nodal status<sup>1</sup>
- The comprehensive comparison of genomic signatures in TransATAC cohort demonstrated that, within the node-negative population, Prosigna defined a low-risk group with lower rates of distant recurrence in years 0–10 (3%) and years 5–10 (1.4%) than other assays<sup>2</sup>
- Recognized in ASCO<sup>3</sup>, ESMO<sup>4</sup>, and NCCN<sup>5</sup> Guidelines and highly recommended by St. Gallen consensus panel<sup>6</sup>

**Please visit us at the ABS Conference on May 13–14 (booth #10) at SEC Glasgow**

Prosigna Breast Cancer Prognostic Gene Signature Assay for use on the nCounter Dx Analysis System is 510(k) cleared and CE-marked for in vitro diagnostic use. See Package Insert in [www.prosigna.com](http://www.prosigna.com) for details.

<sup>1</sup> Laenkholm et al. JCO, 2018;36:735-40  
<sup>2</sup> Sestak L et al. JAMA Oncol. 2018;(4):545-53.  
<sup>3</sup> Harris LN, et al. J Oncol Pract 2016; 12: 384-389  
<sup>4</sup> Senkus E, et al. Ann Oncol 2015 September 1, 2015;26(suppl 5):v8-v30  
<sup>5</sup> [www.nccn.org](http://www.nccn.org)  
<sup>6</sup> Coates AS, et al. Ann Oncol 2015 May 4



Prosigna recommended by NICE for guidance of chemotherapy decisions in early-stage breast cancer patients



## PRESIDENT'S WELCOME



### *Welcome to the 2019 Association of Breast Surgery Conference.*

For the first time we are holding our main conference in Glasgow, although it will be familiar to many as the perennial home of the ABS Trainees Meeting. Glasgow is now a thriving modern city, but it is also steeped in history. It was here in 1895 that George Beatson first performed a bilateral oophorectomy on a patient with advanced breast cancer and he is now widely regarded as the founder of anti-hormonal treatment for breast cancer. The Conference Dinner will be held at the historic Kelvingrove Museum, with the opportunity to browse the galleries that include major art, arms and armour and natural history collections. The Scottish Event Campus (SEC) will provide us with a fantastic venue for our conference.

This is Nicky Roche's first main conference as our Meetings Secretary and together with Lucy Davies she has coordinated a packed and varied programme. We are especially grateful to our international guests, and indeed to all contributors for giving their time to attend and speak at our meeting. Highlights will include Dr Larry Norton from New York speaking on new concepts in tumour growth and metastases and Dr John Kim from Chicago speaking on the topical subject of implant-based breast reconstruction. The conference programme I hope will provide something for everyone and leave you with difficult decisions to make regarding which sessions to attend. Please remember that the talks that you may miss in parallel sessions will soon be available to listen to on the ABS website after the conference.

ABS has established a number of successful ongoing collaborations with other organisations involved in breast care. In Glasgow we are pleased to include sessions jointly organised with the British Association of Plastic, Reconstructive and Aesthetic Surgeons, the UK Breast Cancer Group, Symposium Mammographicum and the newly formed Association of Breast Pathology. The number and quality of the abstracts submitted for the meeting continues to rise year on year. Many of these have been selected for oral presentation, but please also take time to browse the posters. The ABS Conference could not succeed without the generosity and support of our sponsors, so please take the opportunity to visit the extensive trade exhibition.

ABS is continuing to thrive as a specialty association with a growing membership entirely due to the enthusiastic endeavours of its members, committees and Trustees. The ongoing success of our annual meetings is evidence of how ABS has grown. It is fitting that I hand over to Julie Doughty as President here in Glasgow and I wish her well for the next two years.

Enjoy Glasgow 2019.

**Mark Sibbering**  
ABS President

# ABS Conference 13th & 14th May 2019

## MONDAY 13TH MAY 2019 – AT A GLANCE

	SEC Armadillo Auditorium	Lomond Auditorium	Forth
09:00 to 10:30	<b>Session 1:</b> UPDATE ON IMPLANT-BASED BREAST RECONSTRUCTION	<b>Session 2:</b> PRIZE PAPERS SESSION	<b>Session 3:</b> NURSING HOT TOPICS
10:30 to 11:00	Tea and Coffee Break & Poster Viewing (Halls 1 & 2)		
11:00 to 12:30	<b>Session 4:</b> KEY MESSAGES FOR EVERYDAY PRACTICE: CLINICAL PRACTICE AND STANDARDS SESSION	<b>Session 5:</b> FUTURE MANAGEMENT OF DCIS	<b>Session 6:</b> SUBMITTED PAPERS
12:30 to 13:40	Lunch Break & Poster Viewing (Halls 1 & 2)		
12:35 to 13:35		<b>Lunchtime symposium:</b> TREATMENT DE-ESCALATION IN EARLY BREAST CANCER	<b>From 13:00 to 13:30</b> ABS NURSE MEMBERS' MEETING
13:40 to 14:10	<b>Session 7:</b> INVITED LECTURE		
14:15 to 15:45	<b>Session 8:</b> JOINT UK BREAST GROUP & ABS SYMPOSIUM	<b>Session 9:</b> WORKFORCE CHALLENGES	<b>Session 10:</b> SUBMITTED PAPERS
15:45 to 16:15	Tea and Coffee Break & Poster Viewing (Halls 1 & 2)		
16:15 to 16:45	<b>Session 11:</b> INVITED LECTURE		
16:50 to 17:35	<b>Session 12:</b> BREAST CANCER IN THE OLDER PATIENT: WHAT IS THE BEST ADVICE?	<b>Session 13:</b> INNOVATION SYMPOSIUM	<b>Session 14:</b> POSTER PRIZE SESSION
17:40 to 17:50		INTRODUCTION TO THE NEW ABS PRESIDENT	
17:50 to 18:30		ABS AGM	
17:35 to 18:45	Drinks Reception & Poster Viewing (Halls 1 & 2)		

## Monday 13th May 2019

Session 1	
09:00 to 10:30 SEC Armadillo Auditorium	
<b>UPDATE ON IMPLANT-BASED BREAST RECONSTRUCTION</b>	
<i>Chairs: Mr Lee Martin &amp; Miss Shelley Potter</i>	
<b>09:00 to 09:15</b>	<b>GiRFT data on implant loss, revision &amp; adjustment surgery</b> <i>Miss Fiona MacNeill, Royal Marsden Hospital, London</i>
<b>09:15 to 09:35</b>	<b>Current US controversies: Pre-pectoral versus subpectoral, smooth versus textured</b> <i>Dr John Kim, Northwestern Memorial Hospital, Chicago</i>
<b>09:35 to 09:55</b>	<b>Adverse effects in breast implantation - can we avoid them?</b> <i>Dr Lisbet Rosenkrantz Hølmlich, Herlev Hospital, Copenhagen</i>
<b>09:55 to 10:15</b>	<b>We need to talk about capsules</b> <i>Mr Nigel Mercer, Bristol Plastic Surgery</i>
<b>10:15 to 10:30</b>	Discussion



## Session 2

09:00 to 10:30 Lomond Auditorium

### PRIZE PAPERS SESSION

Chairs: Prof John Benson & Mr Stuart McIntosh

09:00 to 09:10	1. The effect of tumour risk and patient factors on the three-year survival for women with early stage triple negative breast cancer (TNBC) in England and Wales: A population based cohort study within National Audit of Breast Cancer in Older Patients (NABCOP) <i>Miss Yasmin Ahmad Jauhari, NABCOP, Clinical Effectiveness Unit, Royal College of Surgeons of England</i>
09:10 to 09:20	2. Development of an end-product evaluation tool for assessment of simulated axillary clearance <i>Dr Keerthini Muthuswamy, Imperial College London</i>
09:20 to 09:30	3. Impact of progesterone receptor status on oncological outcomes in oestrogen receptor positive breast cancer patients – a systematic review and meta-analysis <i>Mr Michael Boland, Royal College of Surgeons of Ireland</i>
09:30 to 09:40	4. Post-mastectomy radiotherapy in patients with immediate breast reconstruction – Results from the iBRA-2 (Immediate Breast Reconstruction and Adjuvant therapy) prospective cohort study <i>Mr Tim Rattay, University of Leicester</i>
09:40 to 09:50	5. Bridging the Age Gap in Breast Cancer - analysis of the impact of comorbidity, dementia and frailty on the rates of surgery in older women <i>Miss Jenna Morgan, University of Sheffield</i>
09:50 to 10:00	6. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in oestrogen receptor positive breast cancer patients <i>Mr Michael Boland, St James Hospital, Dublin</i>
10:00 to 10:10	7. A systematic review and meta-analysis of clinical, patient-reported outcomes and cost of DIEP flap versus implant-based breast reconstruction <i>Mr Ankur Khajuria, University of Oxford</i>
10:10 to 10:20	8. Can we trust our data? A comparative analysis of iBRA and HES data <i>Dr Carla Chamberlain, Royal Marsden Hospital NHS Foundation Trust</i>

FOR YOUR PATIENTS WITH HR+, HER2-, NODE-NEGATIVE, EARLY-STAGE, INVASIVE BREAST CANCER



# Clear on chemotherapy

Treatment decisions supported by prospective 9-year outcomes data<sup>5,6</sup>

Only the Oncotype DX Breast Recurrence Score® test is developed and validated for prediction of chemotherapy benefit.<sup>1-3</sup>

NICE-recommended for early breast cancer patients with node-negative or micrometastatic disease<sup>4</sup>

# NO

CHEMOTHERAPY

# YES

CHEMOTHERAPY

#### References:

1. Paik et al. *J Clin Oncol*. 2006.
2. Sparano and Paik et al. *J Clin Oncol*. 2008.
3. Geyer et al. *npj Breast Cancer*. 2018.
4. © NICE 2018 Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Available from [www.nice.org.uk/guidance/dg34](http://www.nice.org.uk/guidance/dg34). All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
5. Hortobagyi et al. *SABCS 2018*. Poster P3-11-05.
6. Sparano et al. *N Engl J Med*. 2018.

oncotype DX®  
Breast Recurrence Score

HER2=human epidermal growth factor receptor 2 negative;  
HR=hormone receptor positive

Genomic Health, Oncotype DX Breast Recurrence Score, Oncotype IQ, Genomic Intelligence Platform and Making cancer care smarter are trademarks or registered trademarks of Genomic Health, Inc. © 2019 Genomic Health, Inc. All rights reserved. GH11609\_0319\_EN\_UK

Making cancer care smarter.™

oncotype IQ  
Genomic Intelligence Platform

Genomic Health  
LIFE. CHANGING.

### Session 3

09:00 to 10:30 Forth

#### NURSING HOT TOPICS

Chairs: Miss Suzanne Joharchi & Mrs Joanna Rowley

<b>09:00 to 09:20</b>	<b>Implementing shared decision making in the NHS: Lessons from the MAGIC programme</b> <i>Dr Natalie Joseph-Williams, Cardiff University</i>
<b>09:20 to 09:40</b>	<b>Managing increasing workload</b> <i>Mrs Nikki Snuggs, Royal Marsden Hospital</i>
<b>09:40 to 10:00</b>	<b>Breast lymphoedema</b> <i>Ms Katie Riches, Royal Derby Hospital</i>
<b>10:00 to 10:15</b>	<b>Breast cancer - how to feel empowered and take control</b> <i>Ms Liz O'Riordan, Ipswich Hospital NHS Trust</i>
<b>10:15 to 10:30</b>	<b>Discussion</b>

### Session 4

11:00 to 12:30 SEC Armadillo Auditorium

#### KEY MESSAGES FOR EVERYDAY PRACTICE: CLINICAL PRACTICE & STANDARDS SESSION

Chairs: Mr Ashu Gandhi & Miss Michelle Mullan

<b>11:00 to 11:15</b>	<b>New benign guidelines on management of nipple discharge and fibroadenomata</b> <i>Ms Karina Cox, Maidstone &amp; Tunbridge Wells NHS Trust</i>
<b>11:15 to 11:30</b>	<b>The need for a national consent form for breast implant reconstruction</b> <i>Prof Zoë Winters, University College London &amp; Buckinghamshire NHS Trust</i>
<b>11:30 to 11:45</b>	<b>Decision making and consent: Supporting patient choices about health and care</b> <i>Mrs Nicola Cotter, Head of General Medical Council Scotland Office</i>
<b>11:45 to 12:15</b>	<b>Medico-legal case discussions</b> <i>Ms Lauren Sutherland QC, Ampersand Advocates</i>
<b>12:15 to 12:30</b>	<b>Discussion</b>

**SEBBIN** PARIS  
ESTHETIQUE & RECONSTRUCTION


YOUR SAFETY  
OUR PRIORITY

More than 30 years experience


Over 1 million breast implants worldwide

Over 2,000 patients involved in clinical studies


**Zer** ALCL\*  
reported cases to date



Sebbin NanoSkin and micro-textured breast implants



Sebbin round textured breast implants



Sebbin anatomical textured breast implants

[\*] Srinivasa et al. Global Adverse Event Reports of Breast Implant-Associated ALCL: An International Review of 40 Government Authority Databases. *PlastReconstrSurg*. 2017 May;139(5):1029-39. Brody et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. *PlastReconstrSurg*. 2015 Mar;135(3):695-705. Johnson et al. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. *EurJ SurgOncol*. 2017 May 18.

## Session 5

11:00 to 12:30 Lomond Auditorium

### FUTURE MANAGEMENT OF DCIS

*Chairs: Mr James Harvey & Prof Sarah Pinder*

<b>11:00 to 11:15</b>	<b>Overtreatment of DCIS and the need for clinical trials</b> <i>Ms Cliona Kirwan, Manchester University NHS Foundation Trust</i>
<b>11:15 to 11:35</b>	<b>Update on the Sloane Project</b> <i>Prof Alastair Thompson, Baylor College of Medicine, Houston</i>
<b>11:35 to 11:55</b>	<b>Markers which can predict DCIS behaviour and novel therapeutic targets</b> <i>Prof Louise Jones, Barts Cancer Institute, London</i>
<b>11:55 to 12:15</b>	<b>'PRECISION' collaboration</b> <i>Dr Jelle Wesseling, Netherlands Cancer Institute, Amsterdam</i>
<b>12:15 to 12:30</b>	<b>Discussion</b>

## Session 6

11:00 to 12:30 Forth

### SUBMITTED PAPERS

*Chairs: Mr Zenon Rayter & Miss Raghavan Vidya*

<b>11:00 to 11:10</b>	<b>9. Is neoadjuvant radiotherapy prior to mastectomy and autologous reconstruction safe? Comparisons between PRADA trial patients and historical controls</b> <i>Mr Daniel Leff, Imperial College London</i>
<b>11:10 to 11:20</b>	<b>10. Loss rates in sling-assisted implant-based breast reconstruction over time seem to relate to proportion of patients with known risk factors rather than any learning curve</b> <i>Mr Matthew Barber, Edinburgh Breast Unit</i>
<b>11:20 to 11:30</b>	<b>11. Therapeutic mammoplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction, particularly in high-risk patients: Combined analysis of 2,916 patients in the iBRA-2 and TeaM multicentre prospective cohort studies</b> <i>Miss Shelley Potter on behalf of the TEAM Steering Group</i>
<b>11:30 to 11:40</b>	<b>12. Pedicled perforator flaps (LICAP, MICAP) are safe and economical alternatives to mastectomy and complex reconstruction in a select group of patients</b> <i>Miss Radhika Merh, Maidstone and Tunbridge Wells NHS Trust</i>
<b>11:40 to 11:50</b>	<b>13. Patient reported outcomes for latissimus dorsi myocutaneous flap based breast reconstruction – A 10 year experience</b> <i>Miss Shazia Khan, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust</i>
<b>11:50 to 12:00</b>	<b>14. A randomised controlled trial (RCT) of 3-Dimensional simulation of aesthetic outcome in breast conserving treatment (BCT)</b> <i>Miss Amy Godden, Royal Marsden NHS Foundation Trust</i>
<b>12:00 to 12:10</b>	<b>15. Can Strattice™ reduce the long-term incidence of capsular contracture compared to a submuscular implant based breast reconstruction? A prospective multicentre study</b> <i>Ms Rebecca Wilson, Manchester University NHS Foundation Trust</i>
<b>12:10 to 12:20</b>	<b>16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654)</b> <i>Prof Zoë Winters, University College London</i>



Webcasts of most of the presentations from the conference will be available shortly on the ABS website

Personalized medicine helps guide ER+, HER2-, N0 and N+\*, pre- or postmenopausal breast cancer treatment decisions



The **ONLY** test that answers  
three important clinical questions...

Risk at 10 years<sup>1</sup>  
**Can chemotherapy  
be avoided?**

Chemotherapy benefit<sup>2</sup>  
**What is the absolute  
benefit from  
chemotherapy?**

Risk between 5 and 15 years<sup>3</sup>  
**Can the extension of  
endocrine therapy  
be avoided?**

... to now give each of your N0 or N+\* patients  
better treatment and healthcare outcomes

\*N+: micrometastases, 1 to 3 positive lymph nodes



1. Filipits M, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-6020.
2. Sestak L et al. Prediction of Distant Recurrence by EndoPredict in Patients with Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Received Adjuvant Endocrine Therapy plus Chemotherapy (ET+C) or Endocrine Therapy Alone (ET). SABCs 2018.
3. Filipits M, et al. Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years. SABCs 2018.

Myriad Genetics Ltd

The Stanley Building • 7 Pancras Square • London • N1C 4AG  
info@myriadgenetics.co.uk

## Your Trusted Breast Health Partner



RADIOLOGY



BREAST SURGERY



PATHOLOGY



LASER TECHNOLOGY

## Showcasing the latest innovations in Breast Health Solutions and Post-operative Scar Treatment

- **NEW** LOCalizer™ – Wire-free, precision guidance system for breast surgeries
- **NEW** Trident® HD Specimen Radiography System – Verify with confidence - optimised for breast excisions and core biopsies
- Viera™ – Portable Breast Ultrasound system which doesn't compromise on image quality
- Cynosure Icon™ Laser for surgical scar management

Learn more at [www.hologic.com](http://www.hologic.com)

Visit us at  
Stand 19





## Lunchtime symposium

12:35 to 13:35 Lomond Auditorium

### TREATMENT DE-ESCALATION IN EARLY BREAST CANCER

Educational symposium sponsored by Genomic Health UK Ltd



Chair: Dr Alistair Ring

<b>12:35 to 12:40</b>	<b>Chair's introduction</b> <i>Dr Alistair Ring, Royal Marsden Hospital</i>
<b>12:40 to 13:00</b>	<b>How biomarkers can help de-escalate treatment for DCIS</b> <i>Dr Eileen Rakovitch, Sunny Brook Health Science Center, Toronto</i>
<b>13:00 to 13:20</b>	<b>Treatment de-escalation in early invasive breast cancer for node positive patients</b> <i>Dr Marina Parton, Royal Marsden Hospital, London</i>
<b>13:20 to 13:30</b>	<b>Facilitated case study reviews: DCIS, invasive breast cancer, node positive and premenopausal patients</b> <i>Panel discussion</i>
<b>13:30 to 13:35</b>	<b>Closing remarks</b> <i>Dr Alistair Ring, Royal Marsden Hospital</i>

**Lunch will be served outside the Lomond Auditorium for those delegates attending this session**

## Session 7

13:40 to 14:10 SEC Armadillo Auditorium

### INVITED LECTURE

Chair: Prof Chris Holcombe

#### Evolving concepts of risk in prosthetic breast reconstruction

*Dr John Kim, Northwestern Memorial Hospital, Chicago*

## Session 8

14:15 to 15:45 SEC Armadillo Auditorium

### JOINT UK BREAST CANCER GROUP & ABS SYMPOSIUM

Chairs: Miss Julie Doughty & Dr Andreas Makris

<b>14:15 to 14:35</b>	<b>Dose dense chemotherapy</b> <i>Dr Larry Norton, Memorial Sloan Kettering Cancer Center, New York</i>
<b>14:35 to 14:55</b>	<b>Precision treatment for triple-negative breast cancer</b> <i>Dr Peter Schmid, Bart's Hospital</i>
<b>14:55 to 15:15</b>	<b>Recent practice changing trials in early breast cancer</b> <i>Dr Iain MacPherson, Beatson West of Scotland Cancer Centre, Glasgow</i>
<b>15:15 to 15:35</b>	<b>SABCS round up of radiotherapy trials</b> <i>Dr Duncan Wheatley, Royal Cornwall Hospitals NHS Trust</i>
<b>15:35 to 15:45</b>	<b>Discussion</b>

## Session 9

14:15 to 15:45 Lomond Auditorium

### WORKFORCE CHALLENGES

Chairs: Miss Elizabeth Shah & Miss Anne Tansley

<b>14:15 to 14:35</b>	<b>Workforce planning: Breast surgeons in training</b> <i>Mr Tim Cook, Gloucestershire Hospitals NHS Foundation Trust</i>
<b>14:35 to 14:55</b>	<b>Workforce planning in breast diagnostics</b> <i>Dr Nisha Sharma, Leeds Teaching Hospitals NHS Trust</i>
<b>14:55 to 15:10</b>	<b>Working in the UK versus US</b> <i>Prof Alastair Thompson, Baylor College of Medicine, Houston</i>
<b>15:10 to 15:25</b>	<b>Looking after the workforce: Stress &amp; burnout</b> <i>Mr Mark Sibbering, University Hospitals of Derby &amp; Burton</i>
<b>15:25 to 15:30</b>	<b>'Core it out' campaign</b> <i>Miss Leena Chagla, St Helens &amp; Knowsley Teaching Hospitals</i>
<b>15:30 to 15:45</b>	<b>Discussion</b>

## Session 10

14:15 to 15:45 Forth

### SUBMITTED PAPERS

*Chairs: Mrs Joanna Rowley & Mr Maurice Stokes*

<b>14:15 to 14:25</b>	<b>17. Fertility preservation provision for breast cancer patients in England – a postcode lottery</b> <i>Miss Isabella Dash, Aneurin Bevan Health Board, Abergavenny</i>
<b>14:25 to 14:35</b>	<b>18. New model of breast aftercare - Self-supported management</b> <i>Mrs Nicola Stubbs, Manchester Foundation Trust</i>
<b>14:35 to 14:45</b>	<b>19. Surgery and systemic therapy in older women with early stage triple negative breast cancer (TNBC) in England: A population based cohort study within the National Audit of Breast Cancer in Older Patients (NABCOP)</b> <i>Miss Yasmin Ahmad Jauhari, NABCOP, Clinical Effectiveness Unit, Royal College of Surgeons of England</i>
<b>14:45 to 14:55</b>	<b>20. Auricular acupuncture in treating menopausal symptoms caused by breast cancer treatment – a pilot study</b> <i>Ms Hannah Hall, Weston Park Cancer Support Centre, Sheffield</i>
<b>14:55 to 15:05</b>	<b>21. Outcomes of vascularised lymph node transfer for management of breast cancer related lymphoedema</b> <i>Miss Katy Wallis, University Hospital Coventry and Warwickshire</i>
<b>15:05 to 15:15</b>	<b>22. Snakes and Ladders: The highs and lows of the breast cancer journey and clinical nurse specialist intervention</b> <i>Mrs Amanda Lowe, Gloucestershire Hospitals NHS Foundation Trust</i>
<b>15:15 to 15:25</b>	<b>23. Long-term outcomes of bilateral therapeutic mammoplasty - clinical characteristics and quality of life</b> <i>Ms Ewa Majdak-Paredes, Edinburgh Breast Unit</i>
<b>15:25 to 15:35</b>	<b>24. What's best? Team-approach breast care nursing versus 1-1 breast care nursing – you decide!</b> <i>Ms Rachel Pastore &amp; Miss Victoria Rusius, Pennine Acute Hospitals NHS Trust, Manchester</i>

## Session 11

16:15 to 16:45 SEC Armadillo Auditorium

### INVITED LECTURE

*Chair: Mr Mark Sibbering*

#### **New concepts in tumour growth and metastases**

*Dr Larry Norton, Memorial Sloan Kettering Cancer Center, New York*

## Session 12

16:50 to 17:35 SEC Armadillo Auditorium

### **BREAST CANCER IN THE OLDER PATIENT: WHAT IS THE BEST ADVICE?**

*Chairs: Mr Tom Bates & Mr Pud Bhaskar*

<b>16:50 to 17:10</b>	<b>EBCTCG meta-analysis of tamoxifen ± surgery in the elderly</b> <i>Prof Richard Gray, University of Oxford</i>
<b>17:10 to 17:20</b>	<b>Discussant</b> <i>Prof John Robertson, University Hospitals of Derby &amp; Burton</i>
<b>17:20 to 17:35</b>	<b>Discussion</b>

## Session 13

16:50 to 17:35 Lomond Auditorium

### **INNOVATION SYMPOSIUM**

*Chairs: Prof Chris Holcombe and Prof Ramsey Cutress*

<b>16:50 to 17:05</b>	<b>What is health innovation?</b> <i>Mr Ryan Kerstein, BAPRAS Innovation Group</i>
<b>17:05 to 17:15</b>	<b>Innovations in breast surgery and introducing the iBRA-NET innovation group</b> <i>Mr Edward St John, Imperial College London</i>
<b>17:15 to 17:30</b>	<b>Bringing innovation from the lab to the patient: Perspectives from a start-up</b> <i>Mr Jan Beijer, Sirius Medical</i>
<b>17:30 to 17:35</b>	<b>Discussion</b>

## Session 14

16:50 to 17:35 Forth

### POSTER PRIZE SESSION

Chairs: Mr Sankaran Narayanan, Miss Sam Sloan & Mr Soni Soumian

Oral presentation of the best eight posters

## Introduction to the new ABS President and ABS AGM

17:40 to 18:30 Lomond Auditorium

All delegates are invited to an introduction to the new ABS President, Julie Doughty, in the Lomond Auditorium at 17:40. All ABS members are encouraged to stay for the AGM afterwards.



## VISIT US ON STAND 32

We Will Be Displaying The Latest In AI Ultrasound Technology & 3D Specimen Imaging

### MOZART®

#### Specimen Tomosynthesis System

When the goal is to remove the entire tumour in a single procedure with maximum breast conservation.

*"More accurate than 2D X-ray for detecting positive margins."*

MD Anderson Cancer Centre



#### Samsung Ultrasound

Beyond Experience is an integrated solution engineered to offer medical professionals a new and outstanding experience in diagnosis, delivery of enriched views, advanced intelligence, streamlined workflow, and patient centred care.



**SAMSUNG**

TEL: 0208 205 9500 (SALES)

EMAIL: [INFO@MISHEALTHCARE.CO.UK](mailto:INFO@MISHEALTHCARE.CO.UK)

WEB: [WWW.MISHEALTHCARE.CO.UK](http://WWW.MISHEALTHCARE.CO.UK)

## TUESDAY 14TH MAY 2019 – AT A GLANCE

	SEC Armadillo Auditorium	Lomond	Forth
09:00 to 10:30	<b>Session 15:</b> SYMPOSIUM MAMMOGRAPHICUM & ASSOCIATION OF BREAST PATHOLOGY SYMPOSIUM	<b>Session 16:</b> SUCSESSES AND CHALLENGES: UNDERSTANDING YOUR DATA AND INTERPRETING OUTLIERS	<b>Session 17:</b> SECONDARY BREAST CANCER
10:35 to 11:05	<b>Session 18:</b> INVITED LECTURE		
11:05 to 11:35	Tea and Coffee Break & Poster Viewing (Halls 1 & 2)		
11:35 to 13:05	<b>Session 19:</b> MULTIDISCIPLINARY MEETINGS	<b>Session 20:</b> POST MASTECTOMY RADIOTHERAPY: ARE WE OVERTREATING?	<b>Session 21:</b> MAMMARY FOLD SESSION
13:05 to 14:15	Lunch Break & Poster Viewing (Halls 1 & 2)		
13:10 to 14:10		<b>Lunchtime symposium:</b> NEOADJUVANT ENDOCRINE TREATMENT FOR ER POSITIVE HER2 NEGATIVE BREAST CANCER	
14:15 to 15:45	<b>Session 22:</b> NEOADJUVANT CHEMOTHERAPY: MANAGEMENT OF THE AXILLA AND TRIALS	<b>Session 23:</b> ABS & BAPRAS AESTHETIC BREAST SURGERY SESSION	<b>Session 24:</b> SUBMITTED PAPERS

## Tuesday 14th May 2019

Session 15	
09:00 to 10:30 SEC Armadillo Auditorium	
<b>SYMPOSIUM MAMMOGRAPHICUM &amp; ASSOCIATION OF BREAST PATHOLOGY SYMPOSIUM</b>	
<i>Chairs: Mr Philip Turton and Miss Jennifer Rusby</i>	
<b>09:00 to 09:15</b>	<b>ALCL radiological diagnosis</b> <i>Dr Sarah Tennant, Nottingham University Hospitals NHS Trust</i>
<b>09:15 to 09:30</b>	<b>ALCL for surgeons: What to request and when?</b> <i>Prof Louise Jones, Barts Cancer Institute, London</i>
<b>09:30 to 09:45</b>	<b>Current MHRA advice on ALCL</b> <i>Mr Nigel Mercer, Bristol Plastic Surgery</i>
<b>09:45 to 09:55</b>	Discussion
<b>09:55 to 10:25</b>	<b>B3 guidelines MDM</b>  <b>Case presentations</b> <i>Dr Nerys Forester, Royal Victoria Infirmary, Newcastle upon Tyne</i>  <b>Panel discussants</b> <i>Dr Rahul Deb, University Hospitals of Derby and Burton</i> <i>Mr Simon Pain, Norfolk and Norwich University Hospital</i> <i>Dr Sarah Tennant, Nottingham University Hospitals NHS Trust</i>
<b>10:25 to 10:30</b>	Discussion



## Session 16

09:00 to 10:30 Lomond Auditorium

### SUCCESSSES & CHALLENGES: UNDERSTANDING YOUR DATA AND INTERPRETING OUTLIERS

*Chairs: Mr Mysore Chandrashekar & Mr Giles Cunnick*

<b>09:00 to 09:30</b>	<b>NHS BSP &amp; ABS audit of screen detected breast cancers, April 2017 to March 2018: Results &amp; outliers</b> <i>Mr Ashu Gandhi, Manchester University Foundation Trust</i>
<b>09:30 to 09:45</b>	<b>NABCOP update</b> <i>Prof Kieran Horgan, St James's University Hospital, Leeds</i>
<b>09:45 to 10:00</b>	<b>GIRFT outliers - fact or fiction?</b> <i>Miss Tracey Irvine, Royal Surrey County Hospital, Guildford</i>
<b>10:00 to 10:15</b>	<b>Outliers and how do we deal with them</b> <i>Miss Julie Doughty, Gartnavel General Hospital, Glasgow</i>
<b>10:15 to 10:30</b>	<b>Discussion</b>

## Session 17

09:00 to 10:30 Forth

### SECONDARY BREAST CANCER

*Chairs: Mrs Ann Pearson and Prof Deborah Fenlon*

<b>09:00 to 09:20</b>	<b>Honesty when communicating about benefits and harms in metastatic breast cancer</b> <i>Prof Dame Lesley Fallowfield, Brighton &amp; Sussex Medical School</i>
<b>09:20 to 09:40</b>	<b>The role of the Metastatic CNS</b> <i>Mrs Vanda Ribeiro, Royal Marsden Hospital, London</i>
<b>09:40 to 10:00</b>	<b>10% clinical, 90% emotional &amp; practical: The challenges of living with secondary breast cancer</b> <i>Mrs Claire Myerson, Secondary Breast Cancer Patient Representative</i>
<b>10:00 to 10:15</b>	<b>Systemic options in 2019</b> <i>Dr Catherine Harper-Wynne, Maidstone &amp; Tunbridge Wells NHS Trust</i>
<b>10:15 to 10:30</b>	<b>Discussion</b>

## Session 18

10:35 to 11:05 SEC Armadillo Auditorium

### INVITED LECTURE

*Chair: Miss Julie Doughty*

#### Beatson: His life and legacy

*Mr David Smith, retired breast surgeon, Glasgow*

## Session 19

11:35 to 13:05 SEC Armadillo Auditorium

### MULTIDISCIPLINARY MEETINGS

*Chairs: Miss Sarah Downey & Mr Seni Mylvaganam*

<b>11:35 to 11:55</b>	<b>Transforming multidisciplinary team meetings</b> <i>Prof Chris Harrison, The Christie NHS Foundation Trust/ NHSE</i>
<b>11:55 to 12:10</b>	<b>Feedback from disciplines &amp; development of MDM toolkit</b> <i>Mr Mark Sibbering, University Hospitals of Derby &amp; Burton</i>
<b>12:10 to 12:25</b>	<b>Discussion</b>
<b>12:25 to 13:05</b>	<b>Live MDM</b> <b>Case presentations:</b> <i>Miss Nicky Roche, Royal Marsden Hospital</i> <b>Panel discussants:</b> <i>Mr Henry Cain, Royal Victoria Infirmary, Newcastle upon Tyne</i> <i>Dr Nerys Forester, Royal Victoria Infirmary, Newcastle upon Tyne</i> <i>Prof Stephen Johnston, Royal Marsden Hospital, London</i> <i>Prof Sarah Pinder, Guy's Hospital, London</i> <i>Dr Andreas Makris, Mount Vernon Cancer Centre</i> <i>Mrs Nikki Snuggs, Royal Marsden Hospital, London</i>

## Session 20

11:35 to 13:05 Lomond Auditorium

### POST MASTECTOMY RADIOTHERAPY: ARE WE OVERTREATING?

*Chairs: Miss Fiona MacNeill & Mr Laszlo Romics*

<b>11:35 to 12:15</b>	<b>Debate:</b> <b>In the era of treatment de-escalation are we giving too much radiotherapy?</b> <i>Prof David Dodwell, Nuffield Department of Population Health, University of Oxford</i>
	<b>EBCTCG meta-analysis and current PMRT guidelines</b> <i>Prof Ian Kunkler, Western General Hospital, Edinburgh</i>
<b>12:15 to 12:35</b>	<b>Radiotherapy planning for surgeons and late radiation side effects</b> <i>Dr Gillian Ross, Royal Marsden Hospital, London</i>
<b>12:35 to 12:50</b>	<b>Primary radiotherapy and DIEP flap reconstruction</b> <i>Mr Daniel Leff, Imperial College Healthcare NHS Trust</i>
<b>12:50 to 13:05</b>	<b>Discussion</b>

## Session 21

11:35 to 13:05 Forth

### MAMMARY FOLD SESSION

*Chairs: Miss Fiona Langlands & Miss Natasha Jiwa*

<b>11:35 to 11:50</b>	<b>Localisation techniques: ROLL</b> <i>Miss Leena Chagla, St Helens &amp; Knowsley Teaching Hospitals</i>
<b>11:50 to 12:05</b>	<b>Localisation techniques: Iodine-125</b> <i>Mr Adam Critchley, Royal Victoria Infirmary, Newcastle-upon-Tyne</i>
<b>12:05 to 12:20</b>	<b>Localisation techniques: MagSeed v wire</b> <i>Miss Jennifer Rusby, Royal Marsden Hospital, Sutton</i>
<b>12:20 to 12:35</b>	<b>Oncology update on adjuvant extended endocrine treatment and adjuvant bisphosphonates</b> <i>Dr Catherine Harper-Wynne, Maidstone &amp; Tunbridge Wells NHS Trust</i>
<b>12:35 to 12:50</b>	<b>Advice for trainees on getting cosmetic experience</b> <i>Miss Penny McManus, Royal Lancaster Infirmary</i>
<b>12:50 to 13:05</b>	<b>Discussion</b>

## Lunchtime Symposium

13:10 to 14:10 Lomond Auditorium

### NEOADJUVANT ENDOCRINE TREATMENT FOR ER POSITIVE HER2 NEGATIVE BREAST CANCER

*Chair: Prof Daniel Rea*

<b>13:10 to 13:15</b>	<b>Introduction</b> <i>Prof Daniel Rea, University of Birmingham</i>
<b>13:15 to 13:35</b>	<b>Enhancing response to neoadjuvant Letrozole: The PALLET trial</b> <i>Prof Stephen Johnston, Royal Marsden Hospital</i>
<b>13:35 to 13:55</b>	<b>Is there still a role for neoadjuvant chemotherapy in ER positive HER2 negative cancer?</b> <i>Dr Andreas Makris, Mount Vernon Cancer Centre</i>
<b>13:55 to 14:00</b>	<b>Summary</b> <i>Prof Daniel Rea, University of Birmingham</i>
<b>14:00 to 14:10</b>	<b>Discussion</b>

**Lunch will be served outside the Lomond Auditorium for those delegates attending this session**

## Session 22

14:15 to 15:45 SEC Armadillo Auditorium

### NEOADJUVANT CHEMOTHERAPY: MANAGEMENT OF THE AXILLA AND TRIALS

Chairs: Miss Marianne Dillon & Mr Kieran Horgan

<b>14:15 to 14:25</b>	<b>NEST</b> <i>Mr Stuart McIntosh, Queen's University, Belfast</i>
<b>14:25 to 14:35</b>	<b>NOSTRA feasibility</b> <i>Prof Daniel Rea, University of Birmingham</i>
<b>14:35 to 14:55</b>	<b>Axilla consensus guidelines</b> <i>Miss Julie Doughty, Gartnavel General Hospital, Glasgow</i>
<b>14:55 to 15:05</b>	<b>ATNEC</b> <i>Mr Amit Goyal, University Hospitals of Derby &amp; Burton</i>
<b>15:05 to 15:15</b>	<b>The use of ultrasound guided axillary lymph node markers prior to neoadjuvant chemotherapy in node positive breast cancer</b> <i>Dr Kate Downey, Royal Marsden Hospital</i>
<b>15:15 to 15:25</b>	<b>US Experience of TAD</b> <i>Prof Alastair Thompson, Baylor College of Medicine, Houston</i>
<b>15:25 to 15:40</b>	<b>Discussion</b>
<b>15:40 to 15:45</b>	<b>CREST: Cancer Research Excellence in Surgical Trials</b> <p>The NIHR CRN have created the CREST awards to properly recognise high recruiters in oncology trials. The award has been kindly supported by Swann Morton and is for the surgical team or MDT that have made the greatest contribution in recruitment to the oncology portfolio in the year. At the end of the ABS Conference Mr Stuart McIntosh will present this year's award to members of the team from the Queen Elizabeth Hospital, Kings Lynn.</p>

MENTOR® CPG™ Gel Breast Implants

**10 YEARS**  
THAT SHAPED BREAST  
AESTHETICS

A ten year multicentre FDA Core Study.<sup>1</sup>

#1

GLOBAL BRAND<sup>2</sup>



1. Mentor Worldwide, LLC. MemoryShape® Post-Approval Cohort Study (formerly Contour Profile Gel Core Study) Final Clinical Study Report. 02 June 2015.  
2. Based on worldwide market share. Data as of June 2017.  
© www.mentormedical.co.uk

## Session 23

14:15 to 15:45 Lomond Auditorium

### ABS & BAPRAS AESTHETIC BREAST SURGERY SESSION

Chairs: Prof Phil Drew & Mr Mark Henley

<b>14:15 to 14:25</b>	<b>Future collaborations between the ABS and BAPRAS</b> <i>Mr Mark Henley, Nottingham University Hospitals</i>
<b>14:25 to 14:40</b>	<b>Gynaecomastia</b> <i>Mr John Scott, Glasgow Royal Infirmary</i>
<b>14:40 to 15:05</b>	<b>Correction of congenital breast defects</b> <i>Ms Ruth Waters, Queen Elizabeth Hospital, Birmingham</i>
<b>15:05 to 15:30</b>	<b>Technical aspects of nipple sparing mastectomy with different shaped breasts</b> <i>Mr Gerald Gui, Royal Marsden Hospital, London</i>
<b>15:30 to 15:45</b>	<b>Discussion</b>

## Session 24

14:15 to 15:45 Forth

### SUBMITTED PAPERS

Chairs: Mr Matthew Barber & Miss Jennifer Hu

<b>14:15 to 14:25</b>	<b>25. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer</b> <i>Dr Guangdong Xie, Fudan University Shanghai Cancer Center</i>
<b>14:25 to 14:35</b>	<b>26. Surgical management of DCIS during the Sloane Project</b> <i>Miss Cliona Kirwan on behalf of the Sloane Project Group</i>
<b>14:35 to 14:45</b>	<b>27. Multifocality in BRCA-associated breast cancer: A cross-sectional analysis</b> <i>Dr Alan McCrorie, Queen's University Belfast</i>
<b>14:45 to 14:55</b>	<b>28. The Breast Angiosarcoma Surveillance Study (BRASS)</b> <i>Miss Jenny Banks, Torbay and South Devon NHS Foundation Trust</i>
<b>14:55 to 15:05</b>	<b>29. The MagSeed® experience: One year on</b> <i>Miss Judith Reid, University Hospital Crosshouse, Kilmarnock</i>
<b>15:05 to 15:15</b>	<b>30. Interim analysis of an evaluation of clinical outcome and patient and clinician satisfaction with magnetic seeds compared with guide wires for localisation of impalpable breast lesions for surgery</b> <i>Miss Aikaterini Micha, Royal Marsden NHS Trust, Sutton</i>
<b>15:15 to 15:25</b>	<b>31. A combined score of tumour necrosis, tumour budding and tumour-stroma percentage predicts cancer specific survival in primary operable breast cancer</b> <i>Miss Elizabeth Morrow, University of Glasgow</i>
<b>15:25 to 15:35</b>	<b>32. Decoding idiopathic granulomatous mastitis: Have we reached the end of the tunnel?</b> <i>Prof Diptendra Kumar Sarkar, IPGMER, Kolkata</i>



## Conference Evaluation

Delegates are requested to complete their conference evaluation online via the App or the ABS website

[www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)



## INVITED LECTURERS

---

### Dr John Kim

Dr Kim is a Professor of Surgery at Northwestern University Feinberg School of Medicine with a clinical practice that focuses on breast cancer reconstruction. He was educated at Harvard College and received graduate degrees in Medicine and English Literature from Stanford University. He completed an integrated plastic surgery program at Baylor and did his fellowship with Dr Neil Ford Jones at UCLA. He is an Associate Editor of PRS, former Chair of the American Society of Plastic Surgery Breast and Body Symposium, and a visiting professor for the Plastic Surgery Foundation (2019-2010). He has published over 180 peer reviewed papers, holds 16 issued patents, and has founded two start companies on novel medical devices.



### Dr Larry Norton

Dr Larry Norton, MD, Norna S. Sarofim Chair of Clinical Oncology and Senior Vice President, Memorial Sloan Kettering Cancer Center, Medical Director of the Evelyn H. Lauder Breast Center and is Professor of Medicine, Weill-Cornell Medical College. He is a founder of the Breast Cancer Research Foundation and has served as its Scientific Director since the Foundation's inception in 1993. Dr Norton has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences and has served as President of the American Society of Clinical Oncology among other leadership roles in that and other organizations.

Dr Norton has dedicated his life to the eradication of cancer by activities in medical care, laboratory and clinical research, advocacy and government. His research is broad but he is best known for mathematical modeling in therapeutic development. He has been involved in the development of several effective agents including paclitaxel and trastuzumab. He co-invented the Norton-Simon Model of cancer growth which has broadly influenced cancer therapy, and more recently the self-seeding concept of cancer metastasis and growth. He is the Principal Investigator of an NCI Program Project Grant in Models of Human Breast Cancer and an author of more than 350 published articles and many book chapters.

Among many honours, he received ASCO's Karnofsky and Bonadonna Awards, the McGuire Lectureship at the San Antonio Breast Cancer Symposium, MSKCC's Whitmore Award for Clinical Excellence, the Columbia University's Gold Medal for Outstanding Achievement in Medical Research, The Cold Spring Harbor Laboratory Double Helix Award as well as the Thomson Reuters Highly Cited Researcher Certificate.

---

# TRADE EXHIBITION

The Exhibition will be held in Hall 2 and will be open at the following times:

Monday 13th May 2019: 07:45 to 18:45

Tuesday 14th May 2019: 08:30 to 14:15

## Amoena UK

Established in 1975, Amoena is the world's leading breast care brand. As the industry pioneer, Amoena combines technology with supreme comfort, offering an extensive range of bras, swimwear and breast symmetry products.

We work closely with both breast-operated women and surgeons to ensure our recovery care garments reflect the latest surgical techniques and knowledge. The right compression and support is critical in the days following surgery, to help decrease post-operative discomfort, reduce stress on the skin closures and minimise swelling. Our recovery care bras are ideal for breast augmentation, reconstruction and reduction procedures, to aid healing and ensure a perfect result.

[www.amoena.co.uk](http://www.amoena.co.uk)

## AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca has five different sites in the UK, where approximately 6,500 employees work in research and development, manufacturing, supply, medical, sales, and marketing. We supply over 40 different medicines to the NHS, helping to treat approximately one million patients.

## Bosom Buddies

Pauline Giles founded Bosombuddiesuk in 2011 whilst working through her chemotherapy.

Being the third generation of her family who had breast cancer, she'd know the signs right? Like most women in the UK, she thought it was all about a lump. Whilst in hospital with girls in their early 30s, a whole new world of breast awareness information was revealed.

If women do not know they can have breast cancer at an early age, if they don't know how to check themselves, how are they to protect themselves?

Bosombuddiesuk goes into schools to teach 15/16 year old girls, How to Check and Signs and Symptoms of Breast Cancer, to date Pauline has seen in excess of 27,000 girls. With 1 in 8 affected that's over 300 girls who will have breast cancer, but hopefully, detect early and save the heartache of a huge operation.

In the main, it has been Pauline as the driving force. Recently a new Board of Trustees have been appointed and a recruitment drive is underway for more Buddies, as and when finance can be raised.

Bosombuddiesuk has its own skincare range, Puriskin which has recently won two awards, Independent natural skincare brand of the year 2019 and All natural sensitive skincare product UK 2019 for Puriskin Resurfacing Formula. We've taken a step back, to use natural healing herbs like comfrey, which accelerate the skins healing process.

We hope to create a national brand offering quality natural products to those who have endured surgery, with the products making a positive difference by financing our education programme. We hope this is something that hospitals promote.

## Breast Cancer Care & Breast Cancer Now

Breast Cancer Care and Breast Cancer Now have merged to create the UK's first comprehensive breast cancer charity, united around the aim that by 2050 everyone who develops

breast cancer will live and receive the support they need to live well now. We're creating one breast cancer patient focused community, serving the needs of every patient. Our ability to carry out pioneering research and provide life-changing support and care will increase. We'll be able to translate research findings in the labs into new hope on the hospital wards and beyond, whilst increasing the reach of our information and our support networks across the UK.

## BreastHealth UK

BreastHealth UK (stand 25) is an award-winning breast cancer diagnostic company with a difference:

BreastHealth UK is part of Check4Cancer, which was awarded Diagnostic Provider of the Year at the 2018 Health Investor Awards for its managed and audited cancer pathways.

With a rapidly expanding referral base from AXA PPP, Cigna, Vitality and the self-pay market, BreastHealth UK is now looking to recruit more breast surgeons to grow our network of private diagnostic OneStop Breast clinics.

Through our sister company, GeneHealth UK, we also offer a comprehensive genetic service with pre- and post-test counselling for BRCA1& 2 or BreastGene, a panel of 10 clinically relevant breast cancer genes, and insurance claim management.

## Elemental Healthcare

Elemental Healthcare are a leading independent distributor providing innovative solutions in Minimally Invasive Surgery. Elemental's product portfolio is not only at the forefront of the latest developments in surgery but also provides cost effective solutions for a challenged NHS.

Cellis is a truly biological implant at a sensible price. It is preservative

free enabling better integration and reduced issue reaction. Cellis uses non-aggressive purification methods which maintain the dermal integrity. It is easy to use and doesn't require any specialist storage methods or rinsing prior to use.

IFABond Laparoscopic Glue provides an alternative to quilting, significantly reducing the available area for Seroma formation. IFABond is a pure solution with no additives which takes only a short time to form a strong bond. It is quick and easy to apply and is supplied in a variety of formats to suit the application.

T: 0844 412 0020  
W: [www.elementalhealthcare.co.uk](http://www.elementalhealthcare.co.uk)

.....  
**Eurosurgical Ltd**

Eurosurgical Ltd are a UK based supply company for new and established surgical devices, specialising in breast, reconstruction and plastic surgery. We are proud to represent TIGR Matrix which is a 100% synthetic long-term resorbable matrix which is strong over 9 months and fully disappears over 2 years. TIGR is excellent for both pre-pectoral reconstruction and sub-muscular support and is available in a range of sizes that are cost effective and with low reported complications. We also offer a comprehensive range of single-use Fat Grafting equipment and cannulae, including VIBASAT power assisted liposuction for speedy harvesting as well as Aquavage fat collection canisters in 2 different sizes.

.....  
**FaHRAS**

FaHRAS supplies a range of sophisticated evidence-based software that enables a user to run a variety of analyses against a family history to quantify the risk of developing breast cancer.

Supported Risk Assessment Models:  
NICE Guidelines (CG164)  
IBIS  
Manchester  
BOADICEA

Rationalize your referral process today.

.....  
**Flat Friends**

Flat Friends supports women living without breast reconstruction

after mastectomy, including those who face such decisions now or in the future, due to a breast cancer diagnosis or preventative surgery.

We provide support, practical advice and believe that living without reconstruction is a positive outcome.

.....  
**GC Aesthetics Ltd**

Our company is the UK's leading manufacturer of breast implants. We supply thousands of implants every year, changing lives around the globe. We have over 60 years combined market presence with Nagôr and Eurosilicone products. Overall we have 24% of the world market excluding the US, up from 18% just 3 years ago. We work in partnership with the medical community to continually develop high quality products and services that meet both surgeons' and women's needs. As a global leader in the female aesthetics industry, GC Aesthetics not only provides over 1100 products across our brands Eurosilicone® and Nagôr®; but also delivers services to help women make informed choices.

.....  
**Genomic Health UK Ltd**

Genomic Health is the world's leading provider of genomic-based diagnostic tests that help optimise cancer care. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its state-of-the-art scientific and commercial expertise and infrastructure to translate significant amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for more than one million cancer patients worldwide. The company is based in Redwood City, California with international headquarters in Geneva. The UK office is located in London.

For more information please visit [www.GenomicHealth.co.uk](http://www.GenomicHealth.co.uk) or call 020 3031 8087 to request a meeting with one of our representatives.

.....  
**Healthcare 21**

Healthcare 21 is delighted to be a corporate sponsor of ABS this year in Glasgow. We have with us the Lifecell portfolio of acellular dermal matrices including ARTIA™ which has been deliberately designed to optimise breast reconstructive outcomes and STRATTICE™ Pliable (the most clinically studied ADM). We also have the Allergan range of NATRELLE™ Smooth breast implants as well as Lifecell's REVOLVE™, engineered to yield rapid, reliable results in high volume fat processing. Finally, we are delighted to now also be the exclusive UK distributor of the Reco Bra, a unique post-surgical recovery bra suitable for all types of breast cancer, cosmetic breast and cardiothoracic surgeries. We very much look forward to meeting you and introducing you to our portfolio.

.....  
**Hologic**

Hologic is an innovative medical technology company primarily focused on improving women's health and well-being.

We deliver lifechanging and life-saving diagnostic, detection, surgical and medical aesthetic products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision and ever-greater peace of mind.

We are committed to leading in breast health through constant innovation, and are dedicated to evolving our technology to continue serving the needs of our customers and their patients, enabling healthier lives, everywhere, everyday.

.....  
**Ideal Medical Solutions Ltd**

Ideal Medical Solutions Ltd is the UK distributor for the latest and most innovative product for PrePec Breast Reconstruction, The ExaFlex Pocket. Minimise implant exposure to 60 seconds! Suture Free Fixation.

In addition, we have an extensive range of Burns, Plastics, Reconstructive, Aesthetic Surgery and Wound Care products for the NHS and Private sector.

# TRADE EXHIBITORS CONTINUED...

Please visit our stand to find out further information on these clinically proven products: Filtron® Fat Transfer and full range of single use cannulas, Onetrac® single use retractor with built in light source, GalaFLEX® soft tissue support mesh, Tissue glue, Penblade safety scalpels, Viscot surgical marker pens, forceps, single use instruments and our full ENT range.

## Independent Cancer Patients' Voice

Independent Cancer Patients' Voice is a patient advocate group led by patients for patients. We bring the views and experience of cancer patients, their families and carers, to the cancer research community. We believe that clinical research benefits from patients being partners with clinical researchers – rather than passive recipients of healthcare. We have helped shape the design of new clinical trials and tailored patient reported outcome measures to reflect what is really important for patients.

## IGEA Medical Ltd

Through extensive research IGEA have developed CLINIPORATOR™ to deliver Electrochemotherapy. It has been well documented that cutaneous metastases have the greatest impact on a patient's day to day quality of life. CLINIPORATOR™ offers patients with cutaneous and subcutaneous metastases an option to improve quality of life when perhaps other treatments have been exhausted, and can be used alongside conventional chemotherapy.

## Knitted Knockers UK

Knitted Knockers UK is a registered UK charity that knits and crochets breast prostheses for women that have undergone a mastectomy or lumpectomy.

At Knitted Knockers UK, we want women to know that there is a lightweight, 100% cotton alternative to the silicone prosthesis provided by the NHS.

Each Knocker is made with love and filled with hope. They are provided FREE to our recipients.

We also offer Aqua Knockers which allow ladies to swim and exercise with confidence.

All our Knockettes give their time and talents voluntarily to handcraft each knocker to each personalised request.

## Mammary Fold

The Mammary Fold is the national association run by trainees for general and plastic surgery trainees with a specialist interest in breast and oncoplastic breast surgery in the UK.

We were founded in 2003 by surgeons attending the well renowned Glasgow trainees meeting and have developed year on year since then. In 2017 we became officially associated with the ABS and have representation on the ABS Clinical Practice & Standards, Education & Training and Academic & Research Committees.

We are here to educate our members, to advance and promote standards in training in Breast Surgery. Please come and say hello!

## MD Healthcare

State of the art healthcare supplies and consulting.

See [www.mdhealthcaresupplies.uk](http://www.mdhealthcaresupplies.uk) for further information.

## Mentor

As a member of the Johnson & Johnson family of companies, patient safety is our priority at Mentor. That's why we're committed to delivering the highest standards of quality and increased patient outcomes.

Mentor's 10 year data demonstrates our passion to deliver safe products that offer high quality, reliable and state-of-the-art design to enhance breast aesthetic procedures. We are determined to continue to provide objective, clinical information about breast implant safety.

To our Mentor customers and patients, we pledge our commitment to excellence.

## Merit Medical

See [www.merit.com](http://www.merit.com) for further information.

## MIS Healthcare

MIS Healthcare is a UK based exclusive distributor for world leading medical manufacturers, providing state of the art products ranging from high end medical imaging diagnostic equipment, x-ray cabinets for breast surgery, radiology and pathology & medical consumables.

Visit our stand to see the revolutionary 3D Kubtec Mozart x-ray cabinet which is designed for breast surgery with the aim of aiding surgeons in reducing the reoperation rates in breast conservation surgery. We will also be showing our Samsung ultrasound with advanced AI technology further improving diagnostic outcomes.

Our dedication and many years of experience has allowed us to partner with world leading medical manufacturers.

## Myriad Genetics Ltd

Myriad Genetics, a leading molecular diagnostic company founded in 1991 is dedicated to saving and improving lives by discovering and delivering valued, transformative tests across all major diseases.

Myriad's testing portfolio is uniquely qualified to address the following key areas in oncology – cancer prevention, early diagnosis, the development of new treatments and optimisation of current treatments by personalising and increasing effectiveness.

Contact Myriad UK and Ireland  
The Stanley Building, 7 Pancras Square,  
London N1C 4AG, United Kingdom

Office: 00 44 (0) 203 897 6620/6621  
[info@myriadgenetics.co.uk](mailto:info@myriadgenetics.co.uk)  
[www.myriadgenetics.co.uk](http://www.myriadgenetics.co.uk)

## NABCOP

The National Audit of Breast Cancer in Older Patients (NABCOP), commissioned by the Healthcare Quality Improvement Partnership,



evaluates the care received by older women (aged 70+ years) diagnosed with breast cancer in NHS hospitals within England and Wales.

NABCOP's 2019 Annual Report describes the process and outcomes of care for women, diagnosed with breast cancer between 1st January 2014 and 31st December 2017. Patterns for older women are compared to those for women aged 50–69 years. We also distinguish between the groupings: ductal carcinoma in situ; early invasive breast cancer; metastatic breast cancer.

For further information, please visit: [www.nabcop.org.uk](http://www.nabcop.org.uk)

.....  
**NanoString Technologies**

NanoString manufactures reagents and instruments for translational research and molecular diagnostics. The company's nCounter® Analysis System is widely considered the gold standard for gene expression analysis and has been featured in more than 2,500 peer-reviewed publications since its introduction in 2008. The nCounter allows profiling of 100s of targets in a single reaction using innovative molecular barcode technology. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is CE-marked and FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-negative (Stage I or II) and lymph node-positive (1–3 positive nodes Stage II) breast cancer. The Prosigna assay classifies the risk of distant recurrence within 10 years, assuming 5 years of endocrine therapy, based on the PAM50 gene signature, breast cancer subtype, tumour size, nodal status and proliferation score. The National Institute for Health and Care Excellence (NICE) recommends the Prosigna assay to guide adjuvant chemotherapy decisions for people with early breast cancer according to Diagnostics Guidance (DG34).

.....  
**Pfizer Ltd**

At Pfizer Oncology we are committed to the discovery and development of innovative treatments to improve outcomes for cancer patients. We believe that the care and support a

patient receives during their cancer journey is as important as their medication. Our colleagues are passionate about improving patient experience and outcomes and work hard to improve this via patient support materials and programmes.

For more information, please visit [www.pfizer.co.uk](http://www.pfizer.co.uk)

.....  
**pfm medical UK Ltd**

pfm medical offers the full range for Breast Reconstruction, Titanised Meshes TiLOOP Bra and TiLOOP Bra Pocket, and Tissue Matrices, Fortiva and Tutomesh.

TiLOOP® is the extra soft titanised mesh for breast reconstruction, which shows exceptional surgical results and an excellent aesthetic outcome. Our unique titanised meshes are designed for ultimate bio-compatibility and strength. The structure and shape enables easier handling and studies show superior clinical results.

Our range of biological meshes offer a safe and natural option for breast reconstruction. Fortiva Porcine Dermis and Tutomesh Bovine Pericadium.

For more information on the full range, please get in touch [www.pfmmedical.co.uk](http://www.pfmmedical.co.uk)

.....  
**Q Medical Technologies Ltd**

Q Medical Technologies Ltd is an independent UK company founded in 2004. The company occupies premises in Cumbria. In May 2009, Q Medical Technologies Ltd joined the Q Technologies group of companies.

Q Medical distributes and markets a range of medical devices. These include SurgiMend (ADM), Polytech Breast Implants, Ellman Radio Frequency machines, Ellman Medical lasers and Infection Control and Pain Relief products.

We have full representative coverage within the UK and Ireland. Our highly trained and skilled representatives also provide in house clinical training on all products. Additionally we have specialist training available from registered clinicians who provide specialist training as and when required.

.....  
**Raise Healthcare**

Raise Healthcare is a UK based Specialist Medical Device Distributor providing high quality solutions to the healthcare industry. We are the proud, exclusive UK supplier of Braxon® pre shaped porcine acellular dermal matrix (ADM) the first ever Biologic mesh for PRE PECTORAL (Muscle Sparing) Breast Reconstruction. With over 5000 procedures in the EU and over 2500 in the UK, Braxon® has the strongest clinical evidence for pre-pectoral reconstruction. With continued development, we strive to provide the highest quality products at competitive prices, combined with exceptional customer service.

Please visit our booth to learn more about BRAXON and its evidence portfolio.

.....  
**Roche**

Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people's lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services.

In 2017, our total research and development investment in the UK amounted to £338million and we conducted over 181 clinical trials with 10,600 participants. In 2018, we worked together with NICE and NHS England to ensure eight of our new treatments were made available on the NHS. Our drive, every day, is to ensure our medicines reach those who need them as soon as possible.

For more information: [www.roche.co.uk](http://www.roche.co.uk)

.....  
**Sebbin**

Sebbin is a Paris-based medical device company focused on reconstructive and aesthetic surgery. Sebbin has supplied high quality devices for over 30 years and is present in over 60

# TRADE EXHIBITORS CONTINUED...

countries worldwide.

Our comprehensive product portfolio includes silicone breast implants, a unique biological scaffold, a full range of disposable lipofilling devices and single use medical instruments.

We are one of only 3 companies to offer 10-year clinical data on our breast implants. Our new 10-year study is currently the largest prospective breast implant study in the world.

.....

## Sirius Medical

*Born to make things better*

Screening programmes and advanced diagnostics enable detection of cancer at an early stage. We foresee a future where curative treatment of early-stage cancer relies on precisely targeted and minimally invasive surgical procedures that radically remove small tumours, yet spare surrounding healthy tissue.

We are born at the Netherlands Cancer Institute, our solutions are designed in close collaboration with medical professionals: the same experts that treat cancer patients on a daily basis. They recognize the needs and opportunity to optimize and streamline surgical care for cancer patients and inspire us to continuously improve our products and services.

.....

## Smith & Nephew

Smith & Nephew is a diversified advanced medical technology business that supports healthcare professionals in more than 100 countries to improve the quality of life for their patients. We do this by taking a pioneering approach to the design of our products and services, by striving to secure wide access to our diverse technologies for more customers globally, and by enabling better outcomes for patients and healthcare systems.

Please visit us at our stand 20 to see how we continue to support our customers to improve outcomes, constantly striving to create value for healthcare professionals, patients and payers.

01923 477100

E-mail: [customerservicesuk@smith-nephew.com](mailto:customerservicesuk@smith-nephew.com)

[www.smith-nephew.com/uk](http://www.smith-nephew.com/uk)

.....

## Southern Scientific

Southern Scientific has many years of experience and expertise working in the specialist health sector. Indeed, as part of the LabLogic group, the company is a key supplier to the healthcare sector worldwide.

We are the UK manufacturer of the C-Trak Gamma Probe System which provides accurate and precise detection of radiation for use during sentinel node biopsies in breast, melanoma and other types of cancer. We are also the UK supplier of preloaded needles with I-125 seeds for tumour localisation.

.....

## Surgical Indemnity Scheme

SIS members receive comprehensive professional indemnity tailored for UK general surgeons. As a wholly owned subsidiary of the ASGBI, it was developed to deliver the security and expertise you require for all aspects of your NHS and private practice. Benefits include:

- Individual policy of contractual professional indemnity insurance
- 21 years' run off cover following permanent retirement
- Cover includes clinical negligence claims, GMC and disciplinary investigations, inquests, contract disputes and crisis communications
- A 24 hour in-house medico-legal service
- Input from a Clinical Board including practising general surgeons
- Policy meets minimum limit of indemnity requirements in the independent sector

.....

## Systemx UK Ltd

Serving customers for 50 years, our mission is to shape the advancement of healthcare by delivering technological leadership in diagnostic science that makes a genuine difference to the health of people worldwide. In Oncology, Systemx has been focusing on improving breast cancer management through

standardised, molecular lymph node analysis with the NICE approved OSNA® system and radiation-free detection of sentinel lymph nodes with the Sentimag/Magtrace system. Our latest addition, Magseed®, focuses on non-palpable lesion localisation without guide wires. Magseed® can be placed 30 days prior to surgery and accurately removed with the guidance of Sentimag®. Magseed® is available to everyone, everywhere.

[www.systemx.co.uk](http://www.systemx.co.uk)

.....

## Thuasne

SILIMA is Thuasne's flagship brand within breast care. A trusted supplier to the NHS with over 40 years' experience in mastectomy care, the SILIMA range comprises a comprehensive selection of natural-feel breast forms, well-fitting bras and lingerie, and other post-surgery mastectomy products.

.....

## Trulife Ltd

Breast care is where Trulife began over 60 years ago and today, it is still at the heart and soul of everyone at Trulife.

Beginning in 1958 Trulife developed what would become the world's first breast prosthesis. We continue to lead through innovation by creating the most natural and beautiful breast forms available, because women deserve the best. This ethos remains at the heart of everything we do at Trulife. We understand the importance of restoring confidence and self-esteem and consequently improving the quality of life for women following breast surgery. We understand because we listen and have been listening for over 60 years!

.....

## UK Surgical Ltd

Specialist in Surgical Retraction. A small family company based in Sheffield.

The Teasdale Plus double arm Axillar self-retaining retractor system with updated features eliminates old issues with the arms dropping during use. With longer upright post and crossbar it enables the user to

position the retractor mid table for perfect positioning and access.

The new dissecting rack accessory fits into one arm and enables 2 surgeons to perform a bilateral mastectomy simultaneously without any extra surgical assistance. It can also be used in LD Flap and nipple and skin sparing procedures.

Simply put, no other company offers a better retractor system or service. Our range of Supercut scissors are the finest available and can be re-sharpened up to 5 times giving you excellent cutting quality and value for money in these difficult times.

Please make a point to stop by and look at our products.

.....  
**University of Oxford Surgical Intervention Trials Unit**

The Surgical Intervention Trials Unit (SITU) at the University of Oxford draws upon considerable trials and methodological expertise to create a research platform for the development of new surgical trials and innovation across the surgical specialties. Our mission is to advance knowledge and inspire innovation in surgical science research. SITU provides expertise on all aspects of trial design including methodology, grant writing and statistics to develop and design trials addressing a research question involving a surgical intervention, supporting both new and experienced investigators. We are interested in developing trials related to breast surgery, so please come along to discuss with us.

.....  
**YES YES Company**

YES vaginal moisturiser and lubricants have become a valued addition to the survivorship programme. Certified organic, oestrogen free, paraben free, pH and osmotically matched to the vagina, YES VM can safely rehydrate and restore comfort to overcome the distress and discomfort of vaginal dryness caused by cancer treatment. YES WB, water-based and YES OB, plant oil-based lubricants can support sexual wellbeing restoring the comfort and confidence of intimacy after cancer treatment. YES products represent a breakthrough in lubricant technology using natural plant polymers instead of glycerine, mineral oil, propylene glycol or silicone based formulations all of which can cause irritation. Available on prescription or OTC.



*The ABS would like to thank all exhibiting companies for their support of this meeting*

Plastic, Aesthetic & Reconstructive Surgery



Healthcare 21 is delighted to be a sponsor of ABS this year in Glasgow.

We have with us the Lifecell portfolio of acellular dermal matrices including **ARTIA™** which has been deliberately designed to optimise breast reconstructive outcomes and **STRATTICE™ Pliable**. We also have the Allergan range of **NATRELLE™** Smooth breast implants as well as Lifecell's **REVOLVE™**, engineered to yield rapid, reliable results in high volume fat processing.

Finally, we are delighted to now also be the exclusive UK distributor of the **Reco Bra**, a unique post-surgical recovery bra.

We look forward to meeting you and introducing you to our portfolio.

Call +44 (0) 845 605 5521 or visit [www.healthcare21.eu](http://www.healthcare21.eu)

# GENERAL INFORMATION

---

## Registration:

Registration will be open in Hall 1 at the following times:

Monday 13th May 2019: 07:45 to 18:45

Tuesday 14th May 2019: 08:30 to 16:00

---

## Lunch and Refreshments

Lunch and refreshments will be served in Hall 2 at the times listed in the programme.

---

## Media Suite

An A/V Preview Room is available in the Etive Suite for the duration of the meeting. Speakers are requested to hand their presentations into the room on arrival.

---

## Cloakroom

A cloakroom and luggage store will be available in the Alsh suite for the duration of the meeting

---

## Wi-Fi

Delegates can use the free venue wi-fi. Log on to SEC wi-fi network to access this.

---

## Prayer Room

A prayer room is available for the use of delegates. Please ask at registration if you wish to access the room.

---

## ABS Conference App

The ABS Conference App can be downloaded from your app store. It includes programme information, a 'my schedule' facility, speaker information, delegate list and exhibitors list. You can also view the abstracts and electronic posters via the Conference App.

---

## CPD:

The Association of Surgeons of Great Britain and Ireland have awarded 7 points per day for this two day conference.

To access their attendance certificate delegates should complete the online evaluation form on the conference app and they will then be able to download their certificate.



## Asking questions in the SEC Armadillo Auditorium

Delegates wishing to ask a question in the main auditorium can do so via the internet. Please go to <https://www.sli.do> or type Slido into a search engine. Then enter the event code #ABS2019 and you will be able to ask a question of the panel.

---

## Image consent

A photographer will be taking images of the conference during the event for use by the ABS at this meeting, in future publications and on its website. If you do not wish to have images of yourself used by the ABS please let Lucy Davies know by e-mail at [lucydavies@absqbi.org.uk](mailto:lucydavies@absqbi.org.uk)



## Poster sessions:

The electronic posters will be available to browse throughout the conference both on plasma screens in Hall 2 and via the app.

Each poster will also be on display in Hall 2 for part of the conference. The poster sessions will enable delegates to interact with authors about their posters.

The sessions are as follows:

<b>Session 1</b> Monday 13th May 2019	<b>Posters must be displayed from 10:30 to 13:40</b> <i>(authors available from 10:30 to 11:00 and 13:00 to 13:30)</i> <b>Topics: Benign breast disease, breast screening, breast surgery and surgical techniques</b>
<b>Posters on display:</b>	P027, P028, P029, P030, P031, P032, P033, P034, P035, P036, P037, P038, P039, P040, P041, P042, P043, P044, P045, P046, P047, P048, P049, P050, P051, P052, P053, P054, P055, P056, P057, P058, P059, P060, P061, P062, P063, P064, P065, P066, P067, P068, P069, P134, P150, P151, P152, P153, P154, P155, P156, P157, P158, P159
<b>Session 2</b> Monday 13th May 2019	<b>Posters to be displayed from 15:45 to 18:30</b> <i>(authors available from 15:45 to 16:15 and 17:35 to 18:05)</i> <b>Topics: Axilla, basic science, diagnosis/ referral and non surgical treatments</b>
<b>Posters on display:</b>	P001, P002, P003, P004, P005, P006, P007, P008, P009, P010, P011, P012, P013, P014, P015, P016, P017, P018, P019, P020, P021, P022, P023, P024, P025, P026, P070, P071, P072, P073, P074, P075, P076, P077, P078, P079, P080, P081, P082, P083, P086, P087, P088, P089, P090, P091, P092, P093, P095, P096, P097, P098
<b>Session 3</b> Tuesday 14th May 2019	<b>Posters to be displayed from 10:30 to 14:00</b> <i>(authors available from 11:05 to 11:35 and 13:30 to 14:00)</i> <b>Topics: Margins, nursing practice, oncoplastic breast surgery, recurrent disease, risk factors and miscellaneous</b>
<b>Posters on display</b>	P084, P085, P094, P099, P100, P101, P102, P103, P104, P106, P107, P108, P109, P110, P111, P112, P113, P114, P115, P116, P117, P118, P119, P120, P122, P123, P124, P125, P126, P127, P128, P129, P130, P131, P132, P133, P135, P136, P137, P138, P139, P140, P141, P142, P143, P144, P145, P146, P147, P148, P149

All poster authors should ensure that their posters are removed from the boards promptly at the end of their session.

## Social Events:



### Drinks Reception

There will be a drinks reception in Hall 2 on Monday 13th May 2019 from 17:35 to 18:45.

### Annual Dinner

Monday 13th May 2019, Kelvingrove Museum, 7.30pm for 8pm

The ABS Annual Dinner will be held at the Kelvingrove Museum (Argyle Street, Glasgow G3 8AG) on Monday 13th May 2019 at 7.30pm for 8pm. Delegates attending the dinner will be able to browse the galleries for free from 7pm. Attendees must have bought a ticket in advance of the event. The dress code is lounge suits.

A shuttle coach service will run from the turning circle outside the SEC Armadillo between 18:30 and 19:45. A Glasgow Taxis marshal will be available to assist guests to call a taxi after the dinner.



You can follow the ABS on Twitter @ABSGBI. Please tweet during the ABS Conference using the hashtag #ABSConf19 to be included in the Twitter Feed.

**The Association of Breast Surgery would like to thank the following exhibiting companies for their support of the meeting:**

**Main Sponsors**



**Sponsors**



## Diary Dates:

### **ABS Trainees Meeting**

**6th & 7th November 2019**

**Glasgow Royal Infirmary**

Registration will open shortly for the 2019 ABS Trainees Meeting

### **Breast Reconstruction Cadaveric Workshop**

**8th November 2019**

**Clinical Anatomy Skills Centre,  
University of Glasgow**

Mr John Scott, Plastic & Reconstructive Surgeon, will be leading the faculty at the Breast Reconstructive Cadaveric Workshop on the 8th November.

Registration will open shortly for this course.



## **ABS CONFERENCE**

**15th & 16th June 2020 · Bournemouth International Centre**

See the ABS website for further details: [www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)



Association of Breast Surgery  
at The Royal College of Surgeons  
35 – 43 Lincoln's Inn Fields  
London WC2A 3PE

**T** 020 7869 6855  
**E** [office@absgbi.org.uk](mailto:office@absgbi.org.uk)  
**W** [www.associationofbreastsurgery.org.uk](http://www.associationofbreastsurgery.org.uk)